This week we've had Eyes On Commercial Development and the FDA. Several companies have announced partnerships / acquisitions to further boost their pipelines and strengthen their competitive advantage.

This week we've had Eyes On BioPharma updates and US Regulatory moves on EU Tariffs. Check out Lilly 's data and expectations for Verzenio, GSK's deal with Hengrui, Novo Nordisk & Replicate Therapeutics agreement on sRNA, and the latest on US-EU Pharma tariffs.

We've been keeping Eyes On the updates coming out along with the 2Q25 Results. Lots of news on strategic Plans, M&A, Clinical Data, and more. 

Lately, we've kept our Eyes On Sarepta Therapeutics and their discussions with the US FDA regarding their gene therapy Product Elevidys, their pipeline platform. All of this, plus the management shuffles at the FDA itself, has created quite a stir in the industry.